Complete response to first-line osimertinib monotherapy in a complex epidermal growth factor receptor mutant (L833V/H835L) lung adenocarcinoma patient: a case report.
Sign Up to like & getrecommendations! Published in 2023 at "Anti-cancer drugs"
DOI: 10.1097/cad.0000000000001523
Abstract: Although uncommon epidermal growth factor receptor (EGFR) mutations account for 10-15% EGFR mutant non-small cell lung cancer (NSCLC) patients, clinical evidence for uncommon EGFR mutations, such as complex mutations remain limited. In this study, we… read more here.
Keywords: first line; lung; osimertinib monotherapy; l833v h835l ... See more keywords